Neogenomics (NEO) Total Current Liabilities (2010 - 2026)

Neogenomics has reported Total Current Liabilities for 17 years, with the latest figure at $84.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 69.76% year-over-year to $84.6 million; the trailing twelve-month figure through Mar 2026 stood at $84.6 million (down 69.76% YoY), and the FY2025 full-year result was $88.3 million, down 70.69% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $84.6 million, down from $88.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $301.2 million in Q4 2024, with the low at $76.7 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $136.8 million across 5 years, with a median of $92.9 million in 2023.
• The largest YoY upside for Total Current Liabilities was 264.61% in 2025 against a maximum downside of 70.69% in 2025.
• Neogenomics' Total Current Liabilities stood at $89.9 million in 2022, then increased by 7.09% to $96.3 million in 2023, then jumped by 212.8% to $301.2 million in 2024, then plunged by 70.69% to $88.3 million in 2025, then slipped by 4.2% to $84.6 million in 2026.
• The last three Total Current Liabilities figures came in at $84.6 million (Q1 2026), $88.3 million (Q4 2025), and $97.9 million (Q3 2025), per Business Quant data.